Abstract: Coronary artery disease with left main stenosis is associated with the highest mortality of any coronary lesion. Studies in the 1970s and 1980s comparing coronary artery bypass grafting (CABG) and medical therapy showed a significant survival benefit with revascularization. In the angioplasty era, initial experience with percutaneous intervention was associated with poor clinical outcomes. As a result, percutaneous coronary intervention (PCI) was restricted to patients who were considered inoperable, or those with prior CABG with a functional graft to the left anterior descending or circumflex artery ("protected left main disease"). With the introduction of drug-eluting stents, there are new studies demonstrating comparable survival in patients who were revascularized using PCI and CABG, although percutaneous revascularization is associated with a higher rate of repeat revascularization. In the SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) trial, the combined incidence of death, myocardial infarction, and stroke was similar between the CABG and PCI groups; however, the stroke rate was higher in the CABG group. The degree and extent of disease as defined by the SYNTAX scoring system has allowed for stratification of risk and improved assignment of patients with left main stenosis to either PCI or CABG.
NATURAL HISTORY OF LEFT MAIN CORONARY ARTERY DISEASE
Left main coronary artery disease (CAD) is found in 4% to 6% of all patients undergoing coronary angiography. 1, 2 The prognosis of left main CAD is poor. In fact, unprotected left main CAD carries the worst prognosis when compared with single-, double-, or triple-vessel disease, probably because it is frequently associated with severe multivessel disease and an extensive amount of jeopardized myocardium. In the 1970s, studies showed that without revascularization survival of patients with Ͼ50% left main stenosis is 66% at 3 years. 3 The survival is worse with higher grade lesions. When Ͼ70% left main stenosis is present, only 41% of patients survive after 3 years. These numbers underscore the profound importance of the left main coronary artery, and the potential benefit that might be achieved by treating patients with left main stenosis.
EVIDENCE TO SUPPORT REVASCULARIZATION OF LEFT MAIN CAD
The importance of revascularization was established in the 1970s and 1980s from trials that randomly assigned patients with CAD to revascularization with coronary artery bypass grafting (CABG) or to medical management. The first study to compare bypass surgery and medical therapy was the Veterans Administration Cooperative Study, which randomized 686 patients with stable angina to initial CABG or initial medical therapy. 4 Overall, there was a survival benefit for patients assigned to initial CABG. There was a subgroup of 91 patients with left main CAD, and among these patients, survival at 42 months was 88% in the surgical arm and 65% in the medical arm (P ϭ 0.016) 5 ( Fig. 1A) . The benefit was greatest in those patients with left main stenosis Ͼ75%, where survival was 83% in the surgical arm versus 48% in the medical arm (P ϭ 0.036). A substantial benefit was also seen in patients with abnormal left ventricular function, where survival was 89% in the surgical group and 62% if treated medically (P ϭ 0.012).
During the same period, there were 7 randomized trials that compared early CABG to initial medical therapy. The 3 largest trials were the Veterans Administration Cooperative study, 6 the European study, 7 and the Coronary Artery Surgery study. 8 There were 4 smaller trials also. 9 -11 An important meta-analysis that included all 7 trials showed that the mortality of the CABG group was significantly lower than that in the medical group-5-year mortality was 10.2% in the CABG group and 15.8% in the medical group (P ϭ 0.0001). 12 This mortality benefit persisted over time, with the 10-year mortality being 26.4% in the CABG group and 30.5% in the medical group (P ϭ 0.03). Analysis of the left main cohort, which included 175 patients, showed a 68% reduction in mortality at 5 years and a 33% reduction in mortality at 10 years. It was believed that the less-pronounced mortality reduction at 10 years was partially attributable to crossover, as 45% of patients crossed over from the medical group to the CABG group. Interestingly, an analysis of factors associated with extension of survival by revascularization showed that left main CAD was the strongest predictor of increasing life expectancy by revascularization. At 10 years, patients with left main CAD were estimated to have a 20-month increase in survival with revascularization. This is in comparison with the 6-month increase in survival seen in patients with 3-vessel disease and the 11-month increase in survival in patients with abnormal left ventricular dysfunction.
The randomized trials involved a relatively small number of patients. Registry data from a much larger cohort of patients showed similar findings. The Coronary Artery Surgery Study registry included 1484 patients with Ͼ50% left main CAD who were treated with either CABG (1153 patients) or medical therapy (331 patients). The survival at 15 years was 37% for the surgical group, whereas survival was 27% for the medical group 13 (Fig. 1B) . The differential benefit diminished over time because 25% of patients in the medical group ultimately underwent CABG. The overall median survival for CABG patients was 13.3 years versus 6.6 years for patients who were treated with medical therapy.
The main limitations of these studies are that medical therapy did not include statins or angiotensin-converting enzyme inhibitors, and the use of older surgical techniques did not include the use of arterial conduit, off-pump bypass, or a minimally invasive approach. Nonetheless, based on these data, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommended revascularization with CABG as a Class I (level of evidence A) indication as the standard of treatment for patients with significant left main coronary artery stenosis.
PERCUTANEOUS CORONARY INTERVENTION FOR LEFT MAIN ARTERY STENOSIS Early Experience
Percutaneous coronary intervention (PCI) was developed in the late 1970s. In 1978, Andreas Gruntzig reported in The Lancet the first 5 patients who underwent coronary angioplasty. 15 Among these patients, 2 underwent angioplasty of the left main artery. The first left main angioplasty was performed in a 43-year-old man with severe angina pectoris. His initial angiogram showed 80% stenosis of the proximal left main artery. Gruntzig performed left main angioplasty with 2 balloon inflations on November 21, 1977 . The patient's postprocedure angiogram showed a good result. He tolerated the procedure well without complications. There were no electrocardiographic changes or enzyme elevation after the procedure. Gruntzig demonstrated that left main angioplasty was technically feasible. Unfortunately, this patient died of sudden cardiac death about 2 months after the procedure, leading Gruntzig to conclude that "we have not been too successful in dilating stenotic main stems of left coronary arteries. It has been difficult to estimate the extent of disease in this area and the presence of concomitant spasm." 16 In the angioplasty era, the success of percutaneous unprotected left main intervention was poor. One of the largest series included 127 patients with left main CAD treated with percutaneous angioplasty. In this series, successful dilatation was achieved in 94% of patients. 17 Despite the high rate of technical success, survival of patients over time was low with unprotected left main coronary intervention. The 4-year survival was 36% for patients who underwent unprotected left main intervention, a rate comparable with those who were treated with medical therapy. In contrast, patients who underwent protected left main coronary intervention fared reasonably well, with a 4-year survival rate of 90%. Because of these findings, in the 1980s and early 1990s, left main coronary intervention was typically reserved for the following selected group of patients: patients whose left main coronary artery was protected by a functional CABG, and patients who were deemed not to be surgical candidates. The 2006 ACC/AHA guidelines categorized the use of PCI for treatment of unprotected left main CAD as a class III recommendation. 18 Most randomized trials that compared PCI to CABG therapy excluded patients with left main CAD.
New Evidence
Advances in PCI techniques and the introduction of coronary stenting renewed the enthusiasm for percutaneous left main coronary intervention. Initial observational studies showed that with improved technologies, PCI could be performed safely with good intermediateterm outcome. The ULTIMA registry enrolled 279 patients with unprotected left main CAD who were treated with bare-metal stents (BMS). 19 A total of 46% of these patients were deemed inoperable or at high surgical risk. Among these high-risk patients, the 1-year mortality was 24.2%. In this registry, 32% of patients were deemed to be at low risk (age Ͻ65 years with left ventricular ejection fraction Ͼ30% and without shock). In the low-risk cohort, there were no periprocedural deaths and the 1-year mortality rate was only 3.4%.
Contemporaneous observational registries showed similar favorable results when BMS were used to treat unprotected left main CAD. 20 -23 The in-hospital periprocedural mortality ranged from 0% to 4%. Among patients at high risk for CABG, the intermediate-term (1-to 2-year) mortality ranged from 11% to 21%. For patients at low risk for CABG, the intermediate-term mortality ranged from 2.5% to 3.8%. Notably, the rate of restenosis was high (range, 18%-31%), and there was a need for repeat revascularization in 7.3% to 33.6% of the patients. 24 With the advent of drug-eluting stents (DES), the need for repeat revascularization was significantly reduced. Most initial observational studies showed higher frequencies of procedural success and lower rates of angiographic restenosis and target-vessel revascularization when comparing DES with BMS. [25] [26] [27] A randomized controlled trial evaluated 103 patients with unprotected left main CAD with stable angina who received either BMS (50 patients) or a paclitaxel-eluting stent (53 patients). 28 At 6 months, patients who received DES had a significantly lower rate of restenosis (6% with DES vs. 22% with BMS). The rates of major adverse cardiac events were lower in the DES group (13% with DES vs. 30% with BMS). This was driven primarily by a reduction in target-vessel revascularization (2% with DES vs. 16% with BMS).
Studies have shown similar efficacy with different types of DES. Both sirolimus-and paclitaxel-eluting stents are associated with good outcomes. ISAR-LEFT-MAIN (Intracoronary Stenting and Angiographic Results: DES for Unprotected Left Main Lesions) randomized 607 high-risk patients with symptomatic left main CAD to receive a paclitaxel-eluting stent (PES; 302 patients) or a sirolimus-eluting stent (SES; 305 patients).
29 At 1 year, mortality was 6.6% for PES and 5.0% for SES (P ϭ 0.39). The combined primary end point of death, myocardial infarction, or target lesion revascularization was 13.6% in the PES and 15.8% in the SES group (P ϭ 0.44). The rates of definite stent thrombosis were low (0.3% in the PES group and 0.7% in the SES group, P ϭ 0.57). Taken together, these trials showed that coronary stenting of unprotected left main CAD is associated with reasonable outcomes and a good safety profile. The use of DES, either SES or PES, is associated with a reduction in the need for target-vessel revascularization compared with BMS. As stent technology continues to evolve, second-generation DES may yield better results than first-generation DES. Ongoing trials, including ISAR-LEFT-MAIN-2 and Evaluation of Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revasularization (EXCEL), will help address whether everolimus-and zotarolimus-eluting stents are associated with even better PCI outcomes. ). B, Cumulative survival rate in 1484 Coronary Artery Surgery Study (CASS) patients with Ն50% left main coronary artery stenosis who were initially treated with CABG (1153 patients) and nonsurgical therapy (331 patients) (Adapted from Caracciolo et al 13 ).
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The promising results observed with the use of BMS and DES in unprotected left main stenting reopened the possibility that PCI could be a reasonable alternative to CABG. Observational studies from registries showed that when compared with CABG, patients with unprotected left main CAD who were treated with PCI had similar rates of mortality and myocardial infarction. The rates of repeat revascularization were higher in patients treated with PCI. 30 -34 These registries were relatively small and included a large proportion of patients at high risk for surgery. Nevertheless, these findings were corroborated when larger data sets were evaluated.
MAIN-COMPARE (Revascularization of Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization) reported a large registry of 2240 patients in South Korea with left main CAD who underwent either PCI or CABG. 35 The majority of patients in this registry were considered to be at low surgical risk. Propensity matching was used to define 542 matched pairs of patients in PCI and CABG groups with similar baseline characteristics. Among stented patients, 28.9% received BMS and 71.1% received DES. The majority of the CABG group had left main and 3-vessel disease, whereas only one-fourth of the stented group did. At 3 years, after propensity matching, there was no significant difference between the PCI and CABG groups in the risk of death (the hazard ratio for the stenting group was 1.18, with a 95% confidence interval of 0.77-1.80). There was no difference in the composite outcome of death, myocardial infarction, or stroke (hazard ratio for the stenting group, 1.10; 95% confidence interval, 0.75-1.62). Consistent with prior observations, the rate of target-vessel revascularization was significantly higher in the PCI group with a hazard ratio of 4.76 (95% confidence interval, 2.80 -8.11). Not surprisingly, most of these events occurred within the first year. It was also noted that the need for target lesion revascularization was higher in the BMS group compared with the DES group (17.5% for BMS vs. 9.3% for DES). Despite the large sample size, MAIN-COMPARE is an observational study and thus carries all the associated shortcomings and patient selection biases.
RANDOMIZED TRIALS COMPARING PCI AND CABG

LE MANS (Study of Unprotected Left Main Stenting Versus
Bypass Surgery) was the first randomized controlled trial that evaluated the efficacy and safety of PCI versus CABG in patients with left main CAD. LE MANS enrolled 105 patients with left main CAD-52 patients underwent unprotected left main PCI and 53 patients underwent CABG. 36 A total of 35% of patients in the PCI arm were treated with DES. There were more short-term complications within the first month in the CABG arm. The 30-day risk of major adverse cardiac and cerebrovascular events (MACCE) was significantly lower in the PCI group (2% PCI vs. 13% CABG, P ϭ 0.0006). At 1 year, the increase in left ventricular ejection fraction in the PCI group (3.3%) was higher than the CABG group (0.5%), P ϭ 0.047. Survival at 1 year was similar in the 2 groups: 98.1% for PCI and 92.5% for CABG (P ϭ 0.37). The risk of MACCE at 1 year was comparable (relative risk [RR], 1.09 for PCI; 95% confidence interval, 0.85-1.38). The main limitation of LE MANS is the small number of patients studied.
SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) is a prospective, randomized, controlled international multicenter trial comparing PCI using DES (Taxus) with CABG. 37 SYNTAX enrolled 1800 patients with left main CAD or 3-vessel disease. These patients were evaluated by a heart team consisting of an interventional cardiologist and a cardiothoracic surgeon to ensure that revascularization by either approach was deemed possible and equivalent before the patient was enrolled. These patients were randomized to either CABG or PCI with a paclitaxel DES. The trial was designed as a noninferiority trial with the primary end point being the composite of death, stroke, myocardial infarction, or repeat revascularization. At 1 year, mortality was similar between the 2 groups (4.4% PCI vs. 3.5% CABG, P ϭ 0.37). 37 The composite end point of death, myocardial infarction, or stroke was also similar between the 2 groups (7.6% in PCI and 7.7% in CABG, P ϭ 1.00). Stroke rate was higher in the CABG arm (2.2% in CABG vs. 0.6% in PCI, P ϭ 0.003), whereas there was a trend toward higher rates of myocardial infarction in the PCI arm (4.8% in PCI vs. 3.3% in CABG, P ϭ 0.11). At 1 year, the primary end point was significantly higher in the PCI group (17.8% for PCI vs. 12.4% for CABG, P ϭ 0.002). This difference was driven mainly by the need for repeat revascularization, with repeat rates being 13.5% in the PCI group, compared with 5.9% in the CABG group.
The 3-year outcome of SYNTAX continues to show the same findings. 38 There is no significant difference in all-cause death (8.6% PCI vs. 6.7% CABG, P ϭ 0.13). The rate of stroke was higher in the CABG group but the difference by 3 years is no longer statistically significant (2.0% PCI vs. 3.4% CABG, P ϭ 0.07). The rate of myocardial infarction is higher in the PCI group (7.1% with PCI vs. 3.6% with CABG, P ϭ 0.002). Again, the rate of MACCE is higher in the PCI arm (28.0% in PCI vs. 20.2% in CABG, P Ͻ 0.001), driven by an increased need for repeat revascularization (19.7% PCI vs. 10.7% CABG, P Ͻ 0.001). Since follow-up within SYNTAX is still relatively short term, other differences may emerge over subsequent years of follow-up.
The unique aspect of the SYNTAX trial is the use of the SYNTAX score, which is a predefined subgroup analysis. The SYNTAX score measures complexity of a patient's coronary anatomy. 39 This score takes into account anatomic characteristics such as calcification, presence of bifurcated lesions, complete occlusion, the presence of thrombus, and other factors. The score can be calculated using the SYNTAX website (SYNTAX score, available at: www.syntaxscore.com). In the SYNTAX trial, patients were stratified into groups with low, medium, or high SYNTAX scores. Patients with higher SYNTAX scores have more complex lesions. When stratified by SYNTAX score, patients with low (0 -22) score had similar rates of major adverse cardiovascular events at 3 years, irrespective of revascularization method (event rates were 22.5% in CABG and 22.7% in PCI, P ϭ 0.98). The groups with intermediate and high SYNTAX scores had higher major adverse cardiovascular event rates in the PCI arm. In the intermediate risk group (SYNTAX score, 23-32), the event rates were 18.9% in CABG and 27.4% in PCI (P ϭ 0.02). The differences were not statistically significant at 1 year, but the difference became statistically significant by 2 years. In the high-risk group (SYNTAX score Ն33), the 3-year event rates were 19.5% for the CABG group and 34.1% in the PCI group (P Ͻ 0.001). The differences between the 2 groups were evident even at 1 year.
The SYNTAX cohort included patients with left main CAD as well as patients with 3-vessel CAD. The left main subgroup consisted of 705 patients. As the study was a hierarchical design and the primary end point was significantly different (did not achieve noninferiority), the analysis of the left main group can only be considered hypothesis-generating. In this trial, 11% to 14% of patients had isolated left main CAD and a little more than one-third had left main and 3-vessel disease. When analyzed as a separate subgroup, the findings in the left main cohort were slightly different from the main study. At 1 year, the rate of MACCE was not significantly different between the CABG group and the PCI group. 40 The rate of repeat revascularization was higher in those treated with PCI, whereas the rate of stroke was lower in the PCI group. At 3 years, there was no difference in mortality between the 2 groups (7.3% in PCI and 8.4% in CABG, P ϭ 0.64). 41 There was a trend toward higher myocardial infarction rates in the PCI arm
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Revascularization of Left Main CAD (6.9% PCI and 4.1% CABG, P ϭ 0.14). The all-cause death, stroke, and myocardial infarction rates were similar between the 2 groups (CABG 14.3% and PCI 13.0%, P ϭ 0.60, Fig. 2A ). Stroke rate was higher in the CABG arm (4.0% CABG and 1.2% PCI, P ϭ 0.02, Fig.  2B ). The primary end point (MACCE) was higher in the PCI arm, but this difference was not statistically significant (PCI 26.8% vs. CABG 22.3%, P ϭ 0.2, Fig. 2C ). Again, there was a higher rate of repeat revascularization in the PCI arm (20.0% in PCI vs. 11.7% with CABG, P ϭ 0.004, Fig. 2D ). The patients in the left main cohort were stratified into 3 groups by their SYNTAX score (Fig. 3) . In the group with the highest SYNTAX scores (Ն33), the 3-year rate of MACCE was higher in the PCI group. In the group with intermediate SYNTAX scores (score, 23-32) , the 3-year event rates were similar between CABG and PCI. In the group with low SYNTAX scores (ie, 0 -22), there was a trend toward lower cardiovascular event rates in the PCI group, although the difference did not reach statistical significance. These findings support the idea that patients with complex coronary anatomy tend to benefit from CABG, whereas those with simpler coronary anatomy, even with left main CAD, do equally well irrespective of their revascularization strategy.
The Utility of the SYNTAX Scoring System
The utility of predicting cardiovascular events in patients with left main CAD by stratification using the SYNTAX scoring system was independently validated by several studies that collectively involved Ͼ2000 patients. [42] [43] [44] [45] Analysis from an Italian registry that included patients with left main CAD who underwent PCI or CABG showed that a SYNTAX score of 34 was a useful cutoff to identify patients who would derive mortality benefit from surgical revascularization. 43 The 2-year mortality rate was similar in the group with SYNTAX score Յ34, whereas in those with SYNTAX score Ͼ34, patients treated with CABG had significantly lower mortality rate (8.5% in the CABG group vs. 32.7% in the PCI group). The explanation that was proposed for the difference in outcomes is that patients undergoing CABG are more likely to achieve complete revascularization. In this study, all patients, irrespective of their SYNTAX score, were more likely to be completely revascularized if they were in the CABG group. Complete revascularization is important because while early on, coronary events are associated with the stented lesion; over time, nontreated lesion events are more common than stented lesion events. 46 CABG is better at treating the future nontarget lesion events than is PCI, and the degree of revascularization should be a consideration in the selection of patients for either approach.
Combining the SYNTAX Score and the EuroSCORE
In patients with a low SYNTAX score, the rates of MACCE are comparable between CABG and PCI, whereas in those patients with high SYNTAX scores, outcomes are significantly worse with PCI. Although the SYNTAX score is useful in identifying patients at high risk using PCI, the score does not identify patients at risk FIGURE 2. Rates of outcome among patients with left main coronary artery disease in the SYNTAX trial. Cumulative event rates of (A) death, stroke, and myocardial infarction (MI); (B) stroke; (C) major acute cardiovascular and cerebrovascular events (MACCE); and (D) repeat revascularization (Adapted from Serruys 41 and Morice et al 40 ).
using CABG. In fact, the relationship between SYNTAX score and event rates in the CABG group is flat. 47 Rather, the risk of CABG is determined by patient comorbidities. These risks are captured by scoring systems such as the EuroSCORE and the STS score. These are additive scores calculated using objective clinical variables, and they incorporate a variety of risk factors such as age, presence of pulmonary disease, renal function, and neurologic function. The EuroSCORE is a well-validated clinical scoring system that predicts event rates in the CABG group. 48, 49 Interestingly, the EuroSCORE is also an independent predictor of MACCE in the PCI population. 40, 50, 51 As such, the EuroSCORE when used alone is not sufficient for selection of a revascularization strategy, but is effective in identifying patients who are at high risk of mortality and poor outcome, irrespective of whether they are treated by PCI or CABG.
When the SYNTAX scoring system is combined with the EuroSCORE, an interesting observation emerges. When analyzing the SYNTAX population using both the EuroSCORE and the SYNTAX score for the patients with left main CAD, the SYNTAX investigators observed that in patients with complex coronary anatomy, and therefore high SYNTAX score (SYNTAX score Ն33), regardless of their EuroSCORE, patients did better with CABG. 47 The situation is different in those with simple coronary anatomy. In patients with relatively simple left main CAD, and thus low SYN-TAX score (SYNTAX score, 0 -22), the patient's surgical risk appears to affect the outcome. In the low-risk subgroup (Euro-SCORE Ͻ4), patients assigned to CABG fared similarly to those assigned to PCI (MACCE rate 12.3% PCI and 14.5% with CABG). In contrast, in patients at high surgical risk (EuroSCORE Ն4), there was a trend toward better outcome when patients were assigned to PCI. The MACCE rates were 23.5% in the CABG group and 19.4% in the PCI group. This finding did not reach statistical significance, perhaps because of the small number of patients. Nevertheless, these observations support the idea that in patients with suitable anatomy but high surgical risk, PCI may be a good alternative revascularization strategy.
Support for the idea that patients with high surgical risk may benefit from PCI also came from an Italian observational trial evaluating 249 consecutive patients Ͼ80 years with left main CAD undergoing coronary revascularization. 52 CABG was performed in 145 of these patients and 104 patients underwent PCI. Propensity score analysis was performed in an attempt to match the 2 groups. In this study, the rates of cardiac death or myocardial infarction, as well as survival free of major cardiovascular events were similar between the 2 groups, 52 despite the fact that PCI patients were older, had higher creatinine, lower ejection fraction, and a higher mean EuroSCORE.
CONSIDERATIONS REGARDING STRATEGIES FOR REVASCULARIZATION
When deciding between CABG and PCI, the extent of associated CAD is an important consideration. Left main lesions are not all the same-13% occur in isolation, 20% of left main CAD is associated with single-vessel CAD, 31% is associated with 2-vessel disease, and 37% is associated with 3-vessel disease. 40 In the SYNTAX trial, subgroup analysis showed that patients with isolated left main CAD and those with left main and 1-vessel disease tended to have fewer events when revascularized with PCI. On the other hand, patients with left main plus 2-vessel disease and left main with 3-vessel disease tended to have fewer events when revascularized with CABG. 37 Of note, patients with isolated left main and left main with 1-vessel disease had an overall mortality that was significantly lower than patients with 3-vessel disease. Thus mortality is more related to the extent of disease than to the location of the lesions.
Certain patient characteristics also play a role in the selection of CABG versus PCI. For example, subgroup analyses of SYNTAX showed that patients with diabetes tend to have worse outcomes overall. Also, patients with diabetes had significantly increased repeat revascularization rates compared with nondiabetic patients when treated with PCI, but not when treated with CABG. 53 In patients with concomitant valvular disease who are in need of valve replacement, CABG is probably the preferred method of revascularization.
Another consideration is the anatomy of the left main lesion. Half of left main lesions have significant calcifications and this can make PCI technically challenging. Also, Ͼ50% of left main CAD occur in the distal segment and extends into the proximal left anterior descending and left circumflex arteries. 2 When treated with PCI, the distal left main artery is the usual site of restenosis and the circumflex ostium is especially vulnerable to recurrence. 54 A prospective registry of 476 patients in Japan who underwent unprotected left main stenting with SES showed that the location of the left main lesion affects long-term procedural success. In this study, patients with ostial or midbody lesions had a significantly lower rate of target-vessel revascularization compared with those with distal bifurcation lesions at 3 years (3.6% vs. 17.1%, P ϭ 0.0047), although the cardiac mortality at 3 years was similar between the 2 groups. 55 Numerous studies have also shown that a 2-stent technique for bifurcation lesions as compared with a single stent is related to higher complications. The left main artery is no exception and event rates are lower when only one stent is used. Nonetheless, some distal lesions mandate a 2-stent technique due to underlying anatomy and lesion morphology. This factor may be one reason explaining the lower procedural success rate associated with distal lesions.
Several groups have advocated for the use of intravascular ultrasound (IVUS) in guiding left main stenting. IVUS is particularly useful in determining lesion morphology and the true luminal size of the left main artery. It can help ensure optimal expansion of stent. In one retrospective analysis, elective left main stenting with IVUS guidance was shown to reduce long-term mortality rate when compared with conventional angiography.
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GROUPS THAT CAN BE CONSIDERED FOR LEFT MAIN STENTING
Good candidates for left main stenting are patients with isolated left main CAD, left main with 1-vessel disease, and left main CAD with SYNTAX score Ͻ33. Patients with an ostial left main lesion or midbody left main lesion are good candidates. There is also some evidence to suggest that those with left main CAD who are at high risk for CABG could be treated with PCI as an alternative. Because of the importance of dual-antiplatelet therapy in preventing in-stent thrombosis after stenting, these patients need to be compliant with the medical program and have no contraindication to dual antiplatelet therapy for 12 months.
Current guidelines from the ACC/AHA state that unprotected left main PCI is a class IIb (level B) indication for those patients with anatomic conditions that are associated with a low risk from PCI procedural complications and clinical conditions which predict adverse surgical outcomes. 57 In the European guidelines, unprotected left main PCI is now a class IIa (level B) indication. 58 
CONCLUSIONS
In summary, current data support PCI as a reasonable alternative to CABG in patients with left main CAD with simple anatomy. The decision regarding the appropriate strategy for revascularization is complex and needs to be made on a case-by-case basis. Additional randomized trials comparing PCI and CABG in unprotected left main CAD are ongoing. Until additional data demonstrate clearly that one approach is superior, decisions regarding revascularization are best made with a multidisciplinary team approach involving the patient, the patient's primary cardiologist, an interventional cardiologist, and a cardiac surgeon. This is so that the patient can gain a fair and comprehensive understanding of the risks and benefits of the 2 treatment strategies, to make an informed decision.
